Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, two additional trastuzumab biosimilars launched in Europe: Merck & Co.’s Ontruzant and Amgen’s Kanjinti. This series tracks uptake of these trastuzumab biosimilars and medical oncologists’ awareness of these agents in order to gauge their impact on the commercially lucrative breast cancer and gastroesophageal cancer markets. The series investigates perceptions of trastuzumab biosimilars, drivers of and barriers to their use, and future use expectations. Promotional efforts, prescriber and nonprescriber profiles, and benchmarking of these agents’ launch success versus other launched biosimilars are explored to better understand the dynamics of the German biosimilars market.


  • Are German medical oncologists aware of Herzuma, Ontruzant, and Kanjinti?
  • What are the drivers of prescribing of Herzuma, Ontruzant, and Kanjinti?
  • What is the current level of Herzuma, Ontruzant, and Kanjinti use, and how is it changing over time?
  • Are German physicians prescribing Herzuma, Ontruzant, or Kanjinti in combination with Perjeta?
  • Have physicians experienced pressure to prescribe Herzuma, Ontruzant, and Kanjinti?
  • What promotional messages are sales representatives using for Herzuma, Ontruzant, Kanjinti, and Herceptin?


Emerging Biosimilars (Germany) is a three-wave series based on primary research data collected at 1 month, 6 months, and 12 months post-commercial launch with German physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.


Wave 1: September 2018.

Wave 2: February 2019.

Wave 3: July 2019.




A survey of 60 medical oncologists.

Key metrics included

  • Unaided and aided awareness of Herzuma, Ontruzant, and Kanjinti.
  • Familiarity with and impressions of Herzuma, Ontruzant, and Kanjinti.
  • Prescriber and nonprescriber profiles.
  • Willingness to prescribe Herzuma, Ontruzant, and Kanjinti.
  • Performance of Herzuma, Ontruzant, and Kanjinti on key attributes.
  • Sales representative frequency, reach, and satisfaction.
  • Benchmarking against previously launched biosimilars.

Table of contents

  • Oncology: Trastuzumab Biosimilars Launch Tracking (Germany) Wave 2
    • Emerging Biosimilars: Herzuma Launch Tracker (W2)

Author(s): Jimmy Jacob; Marta Delgado, PhD

Jimmy Jacob, is a Business Insights Analyst in the Biosimilars team. Prior to joining DRG, Jimmy worked as a Scientist in Medimmune and Horizon Discovery mostly involving CRIPSR/Cas9 therapeutics. He received his master’s degree in Biotechnology from University of Dundee and his from Imperial College London. His work involved identifying novel molecules that regulated oestrogen receptor-alpha in breast cancer.

Marta Delgado, is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a in Molecular Neuroscience from University College of London (UCL) and a in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.

Related Reports

Biosimilars | Market Events and Forecast | Oncology

In 2018, sales of branded monoclonal antibody biologics in oncology exceeded $20 billion across the major markets (United States, EU5, and J...

View Details

Biomarkers in Oncology | Access & Reimbursement | Detailed, Expanded Analysis: Multi-indication (US)

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant me...

View Details

Biosimilars | Current Treatment | Oncology

In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb

View Details

Biosimilars | Access & Reimbursement | Oncology

This report is available to find out more click the link and fill out the form to get more details.

View Details